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OBJECTIVES The purpose of this study was to evaluate the feasibility of measuring coronary flow velocity
(CFV) by transthoracic Doppler echocardiography (TTDE) in the left anterior descending
coronary artery (LAD) during contrast-enhanced dobutamine stress echocardiography
(DSE). We also assessed the value of TTDE for detecting stress-induced myocardial
ischemia in the LAD territory.
BACKGROUND Noninvasive assessment of both CFV and wall motion during DSE would enhance the
diagnostic accuracy of DSE.
METHODS One hundred forty-four consecutive patients underwent CFV recording in the distal LAD by
TTDE during contrast-enhanced DSE. Regional wall motion score index (WMSI) in the
LAD territory and CFV ratio at peak stress (CFV ratio peak), defined as a ratio of CFV at
peak stress to basal CFV, were obtained.
RESULTS Coronary flow velocity was successfully recorded in 129 patients (90%) at baseline and during
dobutamine infusion. Mean value of CFV ratio peak was 2.39 6 0.83 (range: 0.84 to 4.40).
There was good correlation between WMSI at peak stress and CFV ratio peak (r 5 0.62, p ,
0.001). Coronary flow velocity ratio peak was significantly lower in patients who developed
stress-induced wall motion abnormality (WMA) in the LAD territory than it was in those
patients without WMA (1.51 6 0.51 vs. 2.76 6 0.65, p , 0.001). A CFV ratio peak ,2.1
had a sensitivity of 92% and a specificity of 86% for detecting the presence of stress-induced
WMA.
CONCLUSIONS Assessment of CFV in the distal LAD during DSE is feasible in the majority of cases and
provides a CFV ratio for detecting stress-induced myocardial ischemia in the LAD territory.
(J Am Coll Cardiol 2001;38:117–23) © 2001 by the American College of Cardiology
Assessment of coronary flow velocity (CFV) and CFV
reserve (CFVR) provides information about the functional
significance of coronary artery stenosis and has been useful
for determining the indication or end points of catheter-
based coronary intervention (1–4). These measurements are
usually obtained by sensor-tipped angioplasty Doppler
guidewires, which are only applicable in the cardiac cathe-
terization laboratory. Recent advances in transthoracic Dopp-
ler echocardiography (TTDE) make the measurement of
CFV in the left anterior descending coronary artery (LAD)
feasible with a high success rate. The CFVR in the distal
LAD by TTDE has been assessed using vasodilators like
adenosine and dipyridamole, and its clinical usefulness has
been validated (5–10). We are not aware of any published
studies that measured CFV response during dobutamine
infusion by TTDE. This may be due to the inherent
technical difficulty of measuring flow during augmented
cardiac contraction. Intravenous transpulmonary contrast
agents can improve detection of Doppler flow envelope by
enhancing signal amplitude (5,6,10,11). We undertook this
study to test the following hypotheses: 1) CFV in the LAD
by TTDE can be adequately measured at baseline and
during sequential doses of dobutamine infusion after
transpulmonary contrast agent, and 2) there is good corre-
lation between CFV measured by TTDE and stress-
induced wall motion abnormality (WMA) in the LAD
territory.
METHODS
Study group. One hundred forty-four consecutive patients
(109 men; age: 40 to 94 years; mean age: 67 6 9 years) who
had undergone clinically indicated dobutamine stress echo-
cardiography (DSE) were prospectively studied. The pa-
tients studied were consecutive and unselected. Clinical
indications for DSE include the evaluation of the presence
or severity of myocardial ischemia or myocardial viability.
All patients had symptoms suggestive of angina. Seventy-
eight patients had a previous history of myocardial infarc-
tion. Fifty-two patients had prior coronary revasculariza-
tion. Medications were not withheld before DSE.
Medication included nitrates in 89 patients, calcium chan-
nel antagonists in 45 patients, beta-blockers in 40 patients
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and angiotensin-converting enzyme inhibitors in 44 pa-
tients. Informed consent was obtained from all patients.
DSE. Dobutamine infusion started at 5 mg/kg per min and
increased in 3-min stages up to 40 mg/kg per min. Atropine
was given when required. End points for test termination
were: 1) attainment of target heart rate; 2) completion of
stress protocol; and 3) development of obvious echocardio-
graphic abnormalities. Other reasons for terminating the
test include: 1) arrhythmias such as ventricular tachycardia
or sustained supraventricular tachyarrhythmias; 2) a sub-
stantial increase (.220 mm Hg) or decrease (,80 mm Hg)
in systolic blood pressure; or 3) intolerable symptoms (12).
TTDE. Transthoracic Doppler echocardiography was per-
formed using a commercially available ultrasound machine
(SONOS 5500, Agilent Technologies, Andover, Massa-
chusetts) with a broad-band high-frequency (5 to 12 MHz)
transducer (S12). In B-mode color Doppler flow mapping,
velocity was set in the range of 612 to 615 cm/s, and depth
was adjusted at approximately 6 cm. Color Doppler detec-
tion of LAD flow was obtained as previously described
(8,9). Briefly, the left ventricle was imaged in the low
parasternal long-axis cross section, then the ultrasound
beam was inclined laterally. Next, coronary blood flow in
the distal portion of the LAD was identified as a color-filled
tubular structure in the anterior interventricular sulcus
under the guidance of Doppler color flow mapping. The
long-axis sections were carefully adjusted to minimize the
angle between the Doppler beam and the LAD flow. With
a sample volume positioned on the color signal in the LAD
in diastole, pulsed Doppler signal tracings of flow velocity in
the LAD were recorded (Fig. 1).
Echocardiography contrast enhancement. The contrast
agent for enhancing the left ventricular endocardial border
delineation and Doppler flow signal in the LAD used in this
study was Levovist (Tanabe Seiyaku, Inc., Tokyo, Japan and
Abbreviations and Acronyms
ANOVA 5 analysis of variance
CFV 5 coronary flow velocity
CFVR 5 coronary flow velocity reserve
DSE 5 dobutamine stress echocardiography
LAD 5 left anterior descending coronary artery
MDV 5 mean diastolic velocity
TTDE 5 transthoracic Doppler echocardiography
WMA 5 wall motion abnormality
WMSI 5 wall motion score index
Figure 1. Color Doppler flow mapping of modified low parasternal long-axis view (top left) and spectral Doppler tracing (top right) in distal left anterior
descending coronary artery (LAD) after contrast enhancement. Color-coded blood flow in the LAD is clearly seen (arrow). Spectral Doppler shows biphasic
coronary flow with predominance of diastolic component. Middle and lower panels show an example of another patient with normal response. After
infusion of dobutamine, coronary flow velocity gradually increased. Baseline diastolic mean velocity was 17.2 cm/s, and flow velocity increased to 54.4 cm/s
after injection of atropine; thus, coronary flow velocity ratio peak is 3.16. Speed of recording 100 mm/s, velocity scale 80 cm/s. LV 5 left ventricle.
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Schering AG, Berlin, Germany). The addition of 7 to 8 ml
of sterile water into the 2.5 g of Levovist vial reconstituted
8 ml of Levovist solution (300 mg/ml). A 2-ml injection of
Levovist was administered intravenously as a bolus followed
by a slow saline flush from an in-dwelling cannula inserted
into the antecubital vein.
Study protocol. At baseline, parasternal long- and short-
axis views of the left ventricle in the second harmonic mode
with a broad-band transducer (2 to 4 MHz, S4) was
digitally acquired. Before the contrast injection, intermittent
diastolic triggering every fifth or sixth cardiac beat in the
apical four-chamber view was initiated. Focus was set at the
level of the upper third of the left ventricle to prevent bubble
destruction at the apex. Immediately after the left ventric-
ular cavity was completely filled with contrast, we changed
to the continuous harmonic imaging mode and digitally
acquired an apical four- and two-chamber view. Next, the
S12 probe was used to obtain distal LAD flow under the
Doppler color flow mapping. The same procedure was
repeated at 10 and 20 mg/kg per min of dobutamine
infusion and peak stress. Stress two-dimensional images and
CFV were also obtained at 5, 30 and 40 mg/kg per min of
dobutamine infusion without contrast enhancement.
Echocardiographic measurements. Two-dimensional
echocardiographic monitoring was performed throughout
and up to 10 min after stopping the dobutamine infusion.
Quad-screen format display was created by digitized four-
standard imaging planes at baseline, during low dose of
dobutamine infusion (10 mg/kg per min), intermediate dose
(20 mg/kg per min) and at peak stress. These four images
were also recorded on videotape at the end of each stage.
Side-by-side comparison of wall motion in the digitized
images was performed by one experienced investigator who
was blinded to the patient’s clinical data. Wall motion in
each of the 16 segments of the left ventricle was scored,
ranging from 0 5 hyperkinesis, 1 5 normal to 4 5
dyskinesis. Segments were assigned to a vascular supply on
the basis of a previously described model (13). A test result
was considered positive for ischemia if stress induced an
increase in the wall motion score in one or more segments,
with the exception of a change from akinesis to dyskinesis
(14). Wall motion abnormalities that remained fixed with
stress were considered to represent infarction. The results of
DSE were classified as positive for coronary artery disease if
there was evidence of ischemia or infarction (12). For
assessing regional wall motion in the LAD territory, nine
segments (basal anteroseptal, basal anterior, midinterven-
tricular septum, midanteroseptal, midanterior and four api-
cal segments) were assigned to the LAD territory (13).
These nine segmental scores were summed and divided by 9
to yield a regional wall motion score index (WMSI) at each
stage. According to the results of wall motion response, the
patients were divided into three subgroups: group I—
patients who developed WMA up to intermediate dose
(20 mg/kg per min) of dobutamine infusion; group II—
patients who developed WMA at peak stress; and group
III—patients whose baseline WMA improved or wall mo-
tion became hyperkinetic during dobutamine infusion.
Another experienced observer blinded to the clinical data
performed CFV assessment. Measurements were made
off-line by use of the built-in calculation package of the
ultrasound unit. Diastolic flow envelope was traced, and
mean diastolic velocity (MDV) was obtained at baseline and
during each stage of dobutamine infusion. The CFV ratio
(CFV ratio 5 [10, 20, 30, 40, peak]), defined as the ratio of
MDV during 5 mg/kg per min of dobutamine infusion
(10 mg/kg per min, 20 mg/kg per min, 30 mg/kg per min,
40 mg/kg per min and maximum dose), to basal MDV was
calculated in each patient.
Interobserver measurement variability was determined by
having a second independent observer measure Doppler
velocity recordings at various stages in a group of 20
randomly selected patients. Intraobserver variability was
determined by having one observer remeasure the spectral
envelopes in 20 patients one month apart. Interobserver and
intraobserver variabilities were calculated as the SD of the
differences between two measurements and expressed as a
percent of the average value (9).
Statistical analysis. Continuous data are expressed as
mean 6 SD. The differences among the three groups for the
parametric data were tested by use of analysis of variance
(ANOVA) and then for multiple comparisons using Fish-
er’s protected least-significance difference. Differences in
WMSI and flow velocity between baseline and during
dobutamine infusion were tested with ANOVA with re-
peated measures. Differences between two different para-
metric variables (heart rate, blood pressure) were tested with
paired or unpaired t test, as appropriate. A simple linear
regression analysis was performed between flow and wall
motion variables. We examined the sensitivity and specific-
ity of various cutoff points of the CFV ratio for predicting
stress-induced WMA in the LAD territory. Using receiver
operating characteristic curves, we defined the best cutoff
value for its diagnosis. A probability level ,0.05 was
considered statistically significant.
RESULTS
Doppler evaluation of CFV. All patients completed DSE
without serious complications. Under the guidance of color
Doppler flow mapping, adequate spectral Doppler record-
ings of CFV in the distal portion of the LAD at baseline
and during sequential infusion of dobutamine were obtained
in 129 of 144 study patients (feasibility; 90%) (Fig. 1 and 2).
Coronary flow velocity could be obtained up to the final
stage of dobutamine infusion in 108 of 129 patients (84%)
and one stage before the final stage in 18 patients (14%).
Hemodynamics and wall motion. In 129 patients with
flow velocity recordings, maximum infusion rate of dobut-
amine was 20 mg/kg per min in 6 patients, 30 mg/kg per
min in 28 patients, 40 mg/kg per min in 36 patients and
40 mg/kg per min with atropine in 59 patients, respectively.
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Heart rate increased from 66 6 12 beats/min at baseline
to 127 6 16 beats per min at peak stress (83% of age-
predicted maximum heart rate); systolic blood pressure
increased from 130 6 20 mm Hg to 155 6 33 mm Hg.
Wall motion abnormality in the LAD territory at baseline
was observed in 62 patients. Regional WMSI in the LAD
territory was 1.37 6 0.52 at baseline, which decreased to
1.12 6 0.68 at 10 mg/kg per min of dobutamine, 0.82 6
0.77 at 20 mg/kg per min and 0.78 6 0.84 at peak stress
(p , 0.001, ANOVA). A total of 38 patients developed
stress-induced WMA in the LAD territory. The number of
patients in group I, group II and group III was 16, 22
and 91 patients. Wall motion score index at baseline was
1.77 6 0.60 in group I, 1.47 6 0.60 in group II and 1.28 6
0.45 in group III, respectively (p , 0.001 group I vs. group
III).
Response of CFV. Mean diastolic velocity was 15.4 6 5.8
cm/s (range: 5.3 to 42.3 cm/s) at baseline and 34.9 6 11.8
cm/s (range: 5.9 to 62.9 cm/s) at peak dose. The mean value
of CFV ratio at peak stress (CFV ratio peak) was 2.39 6
0.83 (range: 0.84 to 4.40), and CFV ratio peak was
significantly lower in patients who developed stress-induced
WMA in the LAD territory than it was in those without
(1.51 6 0.51 vs. 2.76 6 0.65, p , 0.001). Coronary flow
velocity ratio in the three subgroups of patients during
sequential infusion of dobutamine is shown in Table 1.
During dobutamine infusion, CFV ratio progressively in-
creased in group III patients, in contrast with the blunted
response in group I patients. Group II patients showed an
intermediate response. The value of CFV ratio in group III
at .20 mg/kg per min of dobutamine infusion became
significantly higher than in group I and group II. Table 2
shows the relation between regional wall motion variables in
the LAD territory and CFV ratio at each stage. At more
than 10 mg/kg per min of dobutamine infusion, there was a
significant correlation between WMSI at peak stress and
CFV ratio (r 5 0.30 to 0.62), and the best correlation was
obtained using CFV ratio at peak stress. A significant
correlation was also noted between DWMSI (WMSI at
baseline minus WMSI at peak stress) and CFV ratio (r 5
0.24 to 0.73). If analysis was confined to patients who had
not taken beta-blockers or patients not administered atro-
pine, these correlations were further improved, especially at
low or intermediate dose of dobutamine. For predicting
stress-induced WMA using CFV ratio, the best cutoff value
of CFV ratio was defined at intermediate and peak dose of
dobutamine infusion (Fig. 3). Coronary flow velocity ratio
(at 20 mg/kg per min) ,1.5 had a sensitivity of 68% (26/38)
and a specificity of 81% (74/91) for the presence of
stress-induced WMA in the LAD territory. Regarding the
17 false positive cases, 12 patients had taken beta-blockers.
The sensitivity and specificity of CFV ratio peak ,2.1 was
92% (35/38) and 86% (78/91), respectively. Regarding the
three false negative cases of CFV ratio peak ,2.1, two
(CFV ratio peak 5 2.97 and 2.57, respectively) had
Figure 2. Example of a patient with stress-induced wall motion abnormality in the left anterior descending coronary artery territory. Increase in coronary
flow velocity is almost lost during dobutamine infusion. Coronary flow velocity ratio peak is 1.08. Note diastolic-systolic flow velocity ratio is inverted during
higher dose of dobutamine infusion. Velocity scale 60 cm/s.
Table 1. CFV Ratio in the LAD During Dobutamine Infusion
Group I Group II Group III ANOVA
CFV ratio
5 mg/kg per min 1.04 6 0.16 0.98 6 0.14 1.05 6 0.15 NS
10 mg/kg per min 1.33 6 0.37 1.28 6 0.25 1.39 6 0.41 NS
20 mg/kg per min 1.32 6 0.35* 1.51 6 0.45* 2.08 6 0.65 , 0.001
30 mg/kg per min 1.29 6 0.38* 1.62 6 0.51* 2.36 6 0.68 , 0.001
40 mg/kg per min 1.00 6 0.11*† 1.65 6 0.57* 2.52 6 0.71 , 0.001
40 mg/kg per min 1 atropine 1.04 6 0.12*† 1.91 6 0.19* 2.73 6 0.62 , 0.001
Peak dose 1.25 6 0.34*† 1.71 6 0.53* 2.76 6 0.65 , 0.001
*p , 0.001 vs. group III; †p , 0.05 vs. group II.
ANOVA 5 analysis of variance; CFV 5 coronary flow velocity; LAD 5 left anterior descending coronary artery.
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dobutamine-induced anterior wall ischemia, and the third
had a CFV ratio peak of 2.12.
Observer variability. Interobserver and intraobserver vari-
abilities for the measurements of CFV recordings were 5.6%
and 6.5%, respectively.
DISCUSSION
This study showed that CFV in the distal LAD could be
measured by TTDE in conjunction with a transpulmonary
contrast agent in the majority of cases during dobutamine
infusion. We also demonstrated that there was a close
correlation between CFV response and wall motion
changes. Coronary flow velocity ratio peak could accurately
predict the presence of stress-induced WMA in the LAD
territory (sensitivity, 92%; specificity, 86%). These results
suggest that the application of CFV measurements during
DSE provides additional noninvasive flow information on
coronary circulation.
Comparison with previous studies. As far as we know,
there are no published studies about CFV response during
Figure 3. Individual value bar graph representing coronary flow velocity (CFV) ratio at 20 mg/kg per min of dobutamine infusion (CFV ratio 20) and CFV
ratio at peak stress (CFV ratio peak) for group I (development of stress-induced wall motion abnormality at intermediate dose), group II (wall motion
abnormality at peak stress) and group III (normal response). Best cutoff line (dotted line) and mean value 6 SD are also shown.
Table 2. Correlation Coefficient Between CFV Ratio and Wall Motion Score Variables
Vs. WMSI at Peak Stress Vs. DWMSI
Overall Beta (2) Atropine (2) Overall Beta (2) Atropine (2)
CFV ratio
5 mg/kg per min r 5 0.08 r 5 0.06 r 5 0.05 r 5 0.16 r 5 0.13 r 5 0.29
10 mg/kg per min r 5 0.30* r 5 0.33† r 5 0.45* r 5 0.24† r 5 0.28† r 5 0.36†
20 mg/kg per min r 5 0.48* (129) r 5 0.54* (91) r 5 0.67* (70) r 5 0.55* r 5 0.61* r 5 0.71*
30 mg/kg per min r 5 0.52* (111) r 5 0.56* (77) r 5 0.65* (55) r 5 0.65* r 5 0.71* r 5 0.78*
40 mg/kg per min r 5 0.51* (84) r 5 0.55* (52) r 5 0.65* (29) r 5 0.66* r 5 0.69* r 5 0.81*
Peak dose r 5 0.62* (129) r 5 0.62* (91) r 5 0.66* (70) r 5 0.73* r 5 0.74* r 5 0.76*
*p , 0.001; †p , 0.01.
Atropine (2) 5 not administered atropine; beta (2) 5 not taken beta-blocker; CFV 5 coronary flow velocity; DWMSI 5 WMSI at baseline 2 WMSI at peak stress;
parenthesis 5 number of patients; WMSI 5 wall motion score index.
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DSE by TTDE. Stoddard et al. (15) demonstrated the
feasibility of pulsed Doppler dobutamine transesophageal
echocardiography for measuring CFV in the proximal LAD
and showed that Doppler coronary flow reserve and wall
motion analysis were equally accurate for detecting signifi-
cant LAD stenosis. However, most of the LAD stenoses are
distal to the LAD segment visualized by transesophageal
echocardiography. Flow velocity measured proximally to a
stenosis may differ from poststenotic flow data, a phenom-
enon related to lower prelesional branch resistance that
directs the flow away from or around the stenosis (2). Thus,
CFVR assessed proximally to the stenosis may underesti-
mate the functional significance of the stenosis severity.
Current study. We demonstrated that adequate quality of
CFV in the distal LAD during DSE could be obtained in
90% of cases. The combined use of Levovist could improve
not only left ventricular endocardial border delineation but
also CFV envelope, thus allowing the simultaneous and
noninvasive assessment of both wall motion and coronary
flow in the LAD territory. Second, we also demonstrated
that responses of CFV correlated well with the changes in
wall motion during dobutamine infusion (Table 2). Our
results reconfirmed the close relation between flow and
function during dobutamine infusion (16,17). Third, this
study showed that CFV ratio was already lower in patients
who developed stress-induced WMA than it was in those
without, even at an intermediate dose of dobutamine
infusion (20 mg/kg per min of dobutamine). That is, there
is a relationship between intermediate-dose abnormalities in
CFV ratio and the eventual ischemic response, and it may
be that abnormalities of CFV ratio are detected earlier than
ischemic wall motion responses. However, there is much
overlap of CFV ratio at an intermediate dose of dobutamine
between patients with and without stress-induced WMA
compared with CFV ratio at peak stress. This overlap is
partly because 30% of patients in this study had taken a
beta-blocker. Beta-blockers are known to attenuate flow
velocity response of dobutamine, especially at low and
intermediate doses. Another possibility is that the develop-
ment of flow abnormality and WMA is a continuum.
Hence, lag time may be short between the onset of
detectable flow abnormality and subsequent ischemic wall
motion response. Nevertheless, early detection of abnormal
coronary flow response may facilitate accurate diagnosis of
stress-induced WMA. Fourth, the value of CFV ratio at
peak stress in patients with normal response of DSE was
nearly the same as previously reported CFVR values ob-
tained in patients without significant LAD stenosis during
adenosine infusion (6,9–11) but lower than that in normal
volunteers (7). Although the mechanisms by which dobut-
amine and adenosine augment coronary flow are distinctly
different, our results suggest that intravenous dobutamine at
doses used for stress testing could also induce maximal
vasodilation in patients with coronary artery disease (18,19).
Further comparative study is needed to validate these
findings.
Study limitations. Some potential methodological limita-
tions need to be addressed in this study. First, we calculated
CFV ratio based on diastolic CFV, not on CFV during the
entire cardiac cycle, but previous studies also calculated
CFVR by diastolic CFV (5,6,8–11). It is difficult to obtain
a complete diastolic flow envelope in some patients, espe-
cially when heart rate .130 beats/min. Augmentation of
myocardial contractility and increase in heart rate produces
a wall motion ghost on the color flow mapping, which
makes it difficult to position the sample volume in the LAD.
Maintenance of the same tomographic plane, Doppler angle
and depth of the sample volume throughout the examina-
tion is mandatory to overcome these problems.
Second, the use of a contrast agent greatly improved the
feasibility of CFV recording, but it produces a bubble noise.
As they disintegrate into the blood stream, agents such as
Levovist appear to aggregate into larger collections of gas,
which are capable of producing a “spike” in the Doppler
spectrum when bubbles are destroyed by the ultrasound
energy. The bubble noise affects accurate tracing of flow
envelope in some cases. Reducing the transmission power
can eliminate some of this noise.
Third, this method was only applicable in the distal part
of the LAD. If patients have isolated diagonal branch
stenosis, there could be a discrepancy between CFV ratio
and induced WMA. Whether this method is applicable in
the other coronary arteries remains to be determined.
Fourth, although we tried to minimize the angle between
the Doppler beam and the LAD flow, we did not perform
angle correction in the Doppler measurement. Hence, there
may have been underestimation of the true velocity. How-
ever, for the purpose of CFV ratio, the absolute velocity
value was not needed because CFV ratio is a quotient of two
velocities.
Clinical implications. This new diagnostic approach, the
combined use of TTDE and contrast-enhanced DSE has
potential in several clinical conditions. It may enhance the
reliability of wall motion analysis, especially when the
development of WMA is subtle. Because of its noninvasive
nature, it has a potential for the serial assessment of flow and
function in patients before and after coronary revasculariza-
tion. It can be used for detecting LAD stenosis in those
conditions such as left bundle branch block, in which
assessment of wall motion alone is difficult or not reliable.
This approach also has merit for assessing myocardial
viability in patients with chronic left ventricular dysfunction
during low-dose dobutamine infusion.
Conclusions. Assessment of CFV in the distal LAD
during DSE was feasible in the majority of cases, and
velocity-derived values correlated well with dobutamine-
induced wall motion changes. Coronary flow velocity ratio
can identify patients who have developed wall motion
abnormalities. These results suggest that CFV measure-
ments in the distal LAD could provide another source of
information for detecting stress-induced myocardial isch-
emia. Further studies are needed to validate its potential.
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